Peramivir is an antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from being released from infected host cells by blocking cleavage of terminal sialic acid residues on host glycoproteins. Structurally it mimics the oxocarbenium ion transition state of the sialic acid cleavage reaction and binds the conserved catalytic pocket of neuraminidase through multiple polar interactions and coordination with active site residues, which provides activity across common influenza A and B neuraminidase subtypes. Peramivir is formulated for intravenous administration, achieves rapid plasma exposure with predominant renal elimination of unchanged drug, and typically requires dosage adjustment in renal impairment. Analytical characterization relies on HPLC, LC-MS and, where required, chiral separation to confirm stereochemical integrity and purity.
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
Parent: Peramivir
![[1,2,4]Triazole-1-carboxamidine Hydrochloride](https://veeprho.com/wp-content/uploads/2024/11/VE0022325-1-2-4-Triazole-1-carboxamidine-Hydrochloride.png "[1,2,4]Triazole-1-carboxamidine Hydrochloride")
Parent: Peramivir
Known related compounds and degradants of peramivir include hydrolytic products, N-dealkylated species, hydroxylated positional isomers, carboxylate derivatives and stereoisomeric impurities; these are routinely detected and characterized by LC-MS and validated HPLC methods. Typical quality specifications aligned with ICH Q3A principles set reporting and identification thresholds based on maximum daily dose and route of administration; in practice this results in reporting thresholds commonly in the 0.05 to 0.1 percent range, individual specified impurity limits commonly 0.1 to 0.2 percent w w, and total impurity limits generally not exceeding about 0.5 percent w w, subject to the product master file and regulatory approvals. Stability studies monitor impurity profiles under forced degradation to define degradation pathways and appropriate storage and formulation controls.
Peramivir is used to treat acute uncomplicated influenza infections; it is administered intravenously when rapid antiviral exposure is needed or when oral or inhaled therapy is not suitable. It is most effective when given early in the course of illness.
Both peramivir and oseltamivir (Tamiflu) are neuraminidase inhibitors and act on the same viral enzyme, but they differ in chemistry, route of administration and pharmacokinetics. Oseltamivir is an oral prodrug converted to an active metabolite, while peramivir is administered intravenously as the active compound; clinical use and dosing differ accordingly.
Peramivir has received FDA approval for treatment of acute uncomplicated influenza in adults; specific labeling and any pediatric or expanded indications should be verified against the current FDA product label and regulatory updates.
Clinical trials show peramivir reduces symptom duration when administered early, with efficacy generally comparable to other neuraminidase inhibitors in head to head studies when given within the recommended treatment window; effectiveness declines if treatment is delayed beyond the early phase of infection.
